ReviewInternational journal of molecular sciences2020
State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.Immunity, inflammation and disease · 2023Pooled it
- Feasibility and safety profile of intranasal third-party allogeneic CD45ROFrontiers in medicine · 2026Trial
- <p>Application of extracellular vesicles in the diagnosis and treatment of chronic obstructive pulmonary disease (Review)</p>.Molecular medicine reports · 2026Review
- Airway Delivery of Encapsulated Cytokine-Secreting Cells for Local Immunomodulation in Inflammatory Lung Diseases.Research square · 2025Article
- Engineerable mesenchymal stem cell-derived extracellular vesicles as promising therapeutic strategies for pulmonary fibrosis.Stem cell research & therapy · 2025Review
- Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025Review
- From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy.Asian journal of pharmaceutical sciences · 2024Review
- The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS.Respiratory research · 2024Article
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease.International journal of molecular sciences · 2023Article
- Inhaled Exosomes Genetically Manipulated to Overexpress CD24 (EXO-CD24) as a Compassionate Use in Severe ARDS Patients.Biomedicines · 2023Article
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
- Special Issue "The Role of Mesenchymal Stem Cells on Inflammatory and Fibrotic Diseases".International journal of molecular sciences · 2023Article
- Imaging drug delivery to the lungs: Methods and applications in oncology.Advanced drug delivery reviews · 2023Review
- MSC-Exosomes Carrying miRNA - Could they Enhance Tocilizumab Activity in Neuropathology of COVID-19?Stem cell reviews and reports · 2023Article
- Application of Precision-Cut Lung Slices as an In Vitro Model for Research of Inflammatory Respiratory Diseases.Bioengineering (Basel, Switzerland) · 2022Review
- Advancing mesenchymal stem cell therapy for asthma towards clinical translation.Annals of translational medicine · 2022Article
- Molecular Insight into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery.International journal of molecular sciences · 2022Review
- Evaluation of Aerosol Drug Delivery Options during Adult Mechanical Ventilation in the COVID-19 Era.Pharmaceutics · 2021Article
- Cellular Immunotherapy and the Lung.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory and pulmonary diseases are among the leading causes of death globally. Despite tremendous advancements, there are no effective pharmacological therapies capable of curing diseases such as COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), and COVID-19. Novel and innovative therapies such as advanced therapy medicinal products (ATMPs) are still in early development. However, they have exhibited significant potential preclinically and clinically. There are several longitudinal studies published, primarily focusing on the use of cell therapies for respiratory diseases due to their anti-inflammatory and reparative properties, thereby hinting that they have the capability of reducing mortality and improving the quality of life for patients. The primary objective of this paper is to set out a state of the art review on the use of aerosolized MSCs and their potential to treat these incurable diseases. This review will examine selected respiratory and pulmonary diseases, present an overview of the therapeutic potential of cell therapy and finally provide insight into potential routes of administration, with a focus on aerosol-mediated ATMP delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.